Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Small Molecule POC Biosensor Technology to Revolutionize Early Disease Detection

By LabMedica International staff writers
Posted on 11 Mar 2024

Aptamers, biosensors made from nucleic acids that bind to specific proteins or small molecules, are increasingly employed in diagnosing various diseases. More...

Their application in cancer detection is particularly promising due to the high cure rate possible with early cancer detection. However, aptamers face significant challenges, such as susceptibility to degradation or aggregation by nucleases and charged proteins found in biological samples like blood or saliva. This limitation has hampered their direct use in clinical samples without prior removal of these molecules. Now, a research team has addressed this issue by using a protein-based microcapsule.

Researchers from Pohang University of Science and Technology (POSTECH, Gyeongbuk, Korea) have devised an aptamer sensor system capable of rapid detection of target molecules directly from biological samples, thus eliminating the need for pretreatment processes. They have developed spherical microcapsules called proteinosomes, based on the self-assembly of protein-polymer amphiphiles. These microcapsules encase an aptasensor featuring a structure-switching aptamer that reacts with target molecules to emit a fluorescent signal instantly. The exterior of the microcapsule consists of a size-selective, semi-permeable membrane, designed to allow only small target molecules through while blocking larger, damaging proteins.

This innovative system maintains the aptasensor's optimal performance in untreated biofluids, thus enabling the efficient and quick detection of targets like estradiol, linked to reproductive organ cancers; dopamine, associated with Parkinson’s and Alzheimer’s diseases; and cocaine, which necessitates rapid detection. The capsules safeguard the aptasensors effectively against harmful proteins. For instance, aptasensors within these microcapsules remained unharmed for 18 hours in high concentration nuclease solutions, much more concentrated than typical serum levels. Moreover, by exploiting each capsule's capability to function as a distinct 'reaction vessel,' the team demonstrated the independent operation of multiple aptasensors in a single mixture. This allows for the simultaneous, real-time sensing of various target molecules and monitoring their concentration changes.

"By integrating sample separation and target detection, we have pioneered a novel small molecule point-of-care biosensor technology that is directly applicable to biological samples such as serum," said Professor Seung Soo Oh who led the research. "This platform has the potential to revolutionize medicine, spanning early disease detection and personalized treatment."

Related Links:
POSTECH


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.